Literature DB >> 8873960

Paget's disease and osteoclast biology.

G D Roodman1.   

Abstract

Paget's disease is the most exaggerated example of bone remodeling in which abnormal osteoclastic bone resorption remains coupled to new bone formation. There are abnormalities in the stages of osteoclast development, and studies in Paget's disease have suggested a major role for IL-6 in human osteoclast activity. The pathophysiologic basis for these abnormalities is not clearly defined, except that the primary cellular abnormality resides in the osteoclast. Many important questions about the pathophysiology of Paget's disease still remain to be answered, including: (1) What is the identity of the virus in pagetic osteoclasts?; (2) Are Paget's patients in different geographical locales harboring a similar virus in their osteoclasts, or can different paramyxoviruses induce Paget's disease?; (3) How is the virus maintained and propagated for many years, so that it can be expressed in the osteoclast, a cell with a finite lifespan?; and (4) Since Paget's disease has a very high familial tendency, with up to 40% of patients having an affected relative, what is the genetic locus associated with Paget's disease, and does this genotype result in an increased propensity for hematopoietic cells such as the osteoclast to harbor paramyxoviruses? The application of the techniques of molecular and cell biology to Paget's disease should provide answers to some of these questions and give important insights into the normal bone remodeling process.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8873960     DOI: 10.1016/8756-3282(96)00211-6

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  6 in total

Review 1.  Paget's disease of bone: diagnosis and treatment update.

Authors:  M Noor; D Shoback
Journal:  Curr Rheumatol Rep       Date:  2000-02       Impact factor: 4.592

2.  Paget's Disease of Bone: A Review of Epidemiology, Pathophysiology and Management.

Authors:  Joseph L Shaker
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

3.  Changes in bone mineral density in patients with Paget's disease treated with risedronate.

Authors:  S Patel; D Pearson; A Bhallah; W Maslanka; D A White; D J Hosking
Journal:  Ann Rheum Dis       Date:  1997-07       Impact factor: 19.103

4.  Inheritance of osteosarcoma and Paget's disease of bone: a familial loss of heterozygosity study.

Authors:  J D McNairn; T A Damron; S K Landas; J L Ambrose; A E Shrimpton
Journal:  J Mol Diagn       Date:  2001-11       Impact factor: 5.568

5.  Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.

Authors:  Keiichiro Kimachi; Hiroshi Kajiya; Shuji Nakayama; Tetsuro Ikebe; Koji Okabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01-12       Impact factor: 3.000

6.  Fusion Potential of Human Osteoclasts In Vitro Reflects Age, Menopause, and In Vivo Bone Resorption Levels of Their Donors-A Possible Involvement of DC-STAMP.

Authors:  Anaïs M J Møller; Jean-Marie Delaissé; Jacob B Olesen; Luisa M Canto; Silvia R Rogatto; Jonna S Madsen; Kent Søe
Journal:  Int J Mol Sci       Date:  2020-09-02       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.